Avanos Medical (NYSE:AVNS) Issues Earnings Results, Beats Expectations By $0.05 EPS

Avanos Medical (NYSE:AVNS) announced its earnings results on Tuesday. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.05, FiscalAI reports. The firm had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.70 million. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. Avanos Medical updated its FY 2026 guidance to 0.900-1.100 EPS.

Avanos Medical Trading Down 1.6%

Shares of AVNS stock opened at $15.22 on Tuesday. The firm’s 50-day simple moving average is $12.86 and its 200-day simple moving average is $12.02. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.38 and a quick ratio of 1.36. Avanos Medical has a 1-year low of $9.30 and a 1-year high of $16.63. The firm has a market cap of $706.33 million, a P/E ratio of -1.49 and a beta of 1.09.

Hedge Funds Weigh In On Avanos Medical

A number of hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC boosted its holdings in Avanos Medical by 22.8% in the third quarter. Armistice Capital LLC now owns 2,500,000 shares of the company’s stock valued at $28,900,000 after acquiring an additional 464,000 shares during the last quarter. State Street Corp lifted its stake in shares of Avanos Medical by 2.8% in the 4th quarter. State Street Corp now owns 1,954,785 shares of the company’s stock valued at $21,952,000 after purchasing an additional 53,523 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Avanos Medical by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 1,084,504 shares of the company’s stock valued at $12,180,000 after purchasing an additional 16,980 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Avanos Medical by 20.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,040,666 shares of the company’s stock worth $11,687,000 after purchasing an additional 176,716 shares during the period. Finally, Millennium Management LLC increased its position in Avanos Medical by 312.4% during the 3rd quarter. Millennium Management LLC now owns 896,242 shares of the company’s stock worth $10,361,000 after purchasing an additional 678,898 shares in the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AVNS. Wall Street Zen upgraded shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. Finally, Zacks Research upgraded Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.